At a glance
(thousands of €, if not stated otherwise) |
Third quarter of 2021 |
Third quarter of 2020 |
Nine months ended 30 September |
Nine months ended 30 September |
Year ended 31 December 2020 |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Income statement(*) |
|
|
|
|
|
||||||
Product net sales |
5,691 |
- |
6,147 |
- |
- |
||||||
Collaboration revenues |
58,503 |
127,519 |
311,711 |
321,923 |
478,053 |
||||||
Cost of sales |
(529) |
- |
(660) |
- |
- |
||||||
R&D expenditure |
(109,196) |
(129,298) |
(378,022) |
(392,199) |
(523,667) |
||||||
S, G&A expenses |
(45,448) |
(43,716) |
(151,267) |
(132,412) |
(185,225) |
||||||
Other operating income |
12,781 |
12,201 |
36,345 |
35,003 |
52,207 |
||||||
Operating loss |
(78,199) |
(33,294) |
(175,747) |
(167,685) |
(178,632) |
||||||
Net financial results |
13,743 |
(49,211) |
33,659 |
(83,355) |
(131,143) |
||||||
Taxes |
(157) |
(14) |
316 |
(723) |
(1,226) |
||||||
Net loss from continuing operations |
(64,613) |
(82,519) |
(141,772) |
(251,763) |
(311,001) |
||||||
Net profit from discontinued operations, net of tax |
- |
614 |
22,191 |
4,215 |
5,565 |
||||||
Net loss |
(64,613) |
(81,905) |
(119,581) |
(247,548) |
(305,436) |
||||||
|
|
|
|
|
|
||||||
Balance sheet |
|
|
|
|
|
||||||
Cash and cash equivalents |
2,834,378 |
2,087,797 |
2,834,378 |
2,087,797 |
2,135,187 |
||||||
Current financial investments |
2,039,787 |
3,220,805 |
2,039,787 |
3,220,805 |
3,026,278 |
||||||
R&D incentives receivables |
149,271 |
122,878 |
149,271 |
122,878 |
135,728 |
||||||
Assets |
5,331,987 |
5,721,086 |
5,331,987 |
5,721,086 |
5,717,731 |
||||||
Shareholders' equity |
2,617,383 |
2,712,082 |
2,617,383 |
2,712,082 |
2,670,355 |
||||||
Deferred income |
2,520,652 |
2,789,183 |
2,520,652 |
2,789,183 |
2,809,133 |
||||||
Other liabilities |
193,952 |
219,821 |
193,952 |
219,821 |
238,242 |
||||||
|
|
|
|
|
|
||||||
Cash flow |
|
|
|
|
|
||||||
Operational cash burn(**) |
(153,546) |
(202,784) |
(376,743) |
(433,270) |
(517,404) |
||||||
Cash flow used in operating activities |
(136,925) |
(180,340) |
(340,056) |
(390,169) |
(427,336) |
||||||
Cash flow generated from/used in (-) investing activities |
311,138 |
(81,084) |
993,191 |
631,720 |
757,288 |
||||||
Cash flow generated from/used in (-) financing activities |
(964) |
353 |
(2,438) |
20,599 |
22,040 |
||||||
Increase/decrease (-) in cash and cash equivalents |
173,249 |
(261,073) |
650,697 |
262,149 |
351,994 |
||||||
Effect of currency exchange rate fluctuation on cash and cash equivalents |
18,489 |
(35,351) |
40,610 |
(35,968) |
(70,539) |
||||||
Cash and cash equivalents at end of the period |
2,834,378 |
2,087,797 |
2,834,378 |
2,087,797 |
2,143,071 |
||||||
Cash and cash equivalents from continuing operations |
2,834,378 |
2,087,797 |
2,834,378 |
2,087,797 |
2,135,187 |
||||||
Cash and cash equivalents classified as assets held for sale |
- |
- |
- |
- |
7,884 |
||||||
Current financial investments at the end of the period |
2,039,787 |
3,220,805 |
2,039,787 |
3,220,805 |
3,026,278 |
||||||
Total current financial investments and cash and cash equivalents at the end of the period |
4,874,165 |
5,308,602 |
4,874,165 |
5,308,602 |
5,169,349 |
||||||
|
|
|
|
|
|
||||||
Financial ratios |
|
|
|
|
|
||||||
Number of shares issued at the end of the period |
65,530,121 |
65,340,842 |
65,530,121 |
65,340,842 |
65,411,767 |
||||||
Basic and diluted loss per share (in €) |
(0.99) |
(1.25) |
(1.83) |
(3.81) |
(4.69) |
||||||
Share price at the end of the period (in €) |
45.16 |
121.20 |
45.16 |
121.20 |
80.48 |
||||||
Total group employees at the end of the period (number)(***) |
1,319 |
1,407 |
1,319 |
1,407 |
1,489 |
||||||
|
|||||||||||
Employees per site as of 30 September 2021
(total: 1,319 employees)
